Document is current
Any future updates will be listed below
-
Authors
Sunnåker, Mikael
Bhattacharya, Chandrali
Nelander, Karin
Aurell, Malin
Heijer, Maria
Collén, Anna
Han, David
Holden, Julie
Trebski, Monika
Garkaviy, Pavlo
Ericsson, Hans
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04232345 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers
https://doi.org/10.1007/s40261-024-01402-x
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Accepted: 14 October 2024
First Online: 4 November 2024
Declarations
:
: This study was funded by AstraZeneca.
: MS, CB, KN, MA, MH, AC, MT and HE are employees and stockholders of AstraZeneca. PG and JH were employees and stockholders of AstraZeneca when the study was conducted. DH is an employee of PAREXEL, which received funding from AstraZeneca for the conduct of this study.
: The study was performed in accordance with ethical principles that had their origins in the Declaration of Helsinki and were consistent with the International Conference on Harmonisation Good Clinical Practice and the AstraZeneca policy on Bioethics and Human Biological Samples. The study was approved by Aspire IRB, LLC, 11491 Woodside Avenue, Santee, CA 92071, USA (ASPIRE<sup>®</sup> Protocol #2019336727, 27 December 2019).
: All participants provided written informed consent before entering the study.
: All participants provided written informed consent for their anonymised data to be published.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data-sharing policy described at .
: Not applicable.
: Substantial contributions to study conception and design: HE, PG, KN. Substantial contributions to analysis and interpretation of the data: MS, JH, MT, DH, PG, CB, HE. Drafting the article or revising it critically for important intellectual content: all authors. Final approval of the article to be published: all authors.
